CapacitytoCure
At Poseida Therapeutics, we are boldly developing new solutions to redefine treatment paradigms for life-threatening cancers and genetic diseases. We have designed our genetic engineering technologies to represent the future of innovation in cell and gene therapies, giving new hope to patients.
At Poseida Therapeutics, we are boldly developing new solutions to redefine treatment paradigms for life-threatening cancers and genetic diseases. We have designed our genetic engineering technologies to represent the future of innovation in cell and gene therapies, giving new hope to patients.
x
Audio
International Myeloma Society (IMS) Fireside Chat
Tune in to hear leading multiple myeloma experts discuss interim
Phase 1 results for allogeneic CAR-T therapy P-BCMA-ALLO1 and
the potential significance for multiple myeloma patients.
TECHNOLOGY
A Suite of Differentiated Genetic Engineering Platforms
Our non-viral piggyBac® DNA Delivery System inserts large genetic payloads into the genome. Our Cas-CLOVER™ Site-Specific Gene Editing System can be leveraged to make accurate site-specific deletions, insertions, and knock-ins in multiple cell types.
Video
Thomas G. Martin, M.D., discusses case of reactivation of CAR-T Therapy with a T-Cell Engager in Relapsed Multiple Myeloma
Thomas G. Martin, M.D., discusses case of reactivation of CAR-T Therapy with a T-Cell Engager in Relapsed Multiple Myeloma
ABOUT US
Poseida Stands Apart
Our leadership team combines long-standing scientific expertise with the strategic insight needed to advance the company forward and deliver novel therapeutics for patients.
PIPELINE
Cell Type Matters
Our gene editing technologies and delivery platforms allow us to target many different cell types to treat cancer and genetic diseases. By focusing on specific cell populations, we can potentially advance fully allogeneic CAR-T therapies with an early memory phenotype for patients fighting cancer or develop functional cures for rare genetic diseases.
Latest News and Updates
Poseida Therapeutics Highlights Positive Interim Phase 1 Results for P-BCMA-ALLO1 and Preclinical Data for Dual CAR-T P-CD19CD20-ALLO1 at the 66th American Society of Hematology (ASH) Annual Meeting
December 9, 2024
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
November 26, 2024
Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline
November 14, 2024